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Introduction 
Lipid disorders encompass a broad spectrum of 
metabolic conditions that affect blood lipid levels 
They are generally characterized by elevated levels of 
cholesterol, triglycerides, and/or lipoproteins in 
the blood in association with an increased risk of 
(or current) cardiovascular disease 
Dyslipidemia  
Incidence  
 
29.3%  - 53%  of adults have dyslipidemia 
 
 
The majority of lipid disorders are acquired 
through unhealthy lifestyles (obesity, 
inactivity, alcoholism, etc) 
Hereditary (familial) causes are less common  
 
Fredrickson Classification of Familial 
Hyperlipidemia 
Familial 
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Relative Prevalence of Familial Forms 
of Hyperlipoproteinemia 
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Aquired (Secondary) Dyslipidemia 
Causes  
 • Uncontrolled type 1 or type 2 diabetes mellitus 
• Endocrine disorders: metabolic syndrome, 
hypothyroidism, hypercortisolism 
• Medications: steroids, estrogen, second generation 
antipsychotic, antidepressants, accutane, 
thiazolidinediones, thiazides, beta-blockers, bile acid 
sequesterants, immunodepressents (sirolimus), 
antiretroviral therapy 
• Pregnancy 
• Renal disease: nephrotic syndrome, renal failure 
• Liver disease: chronic hepatitis with fatty liver 
• Excessive alcohol intake 
Purpose 
 
 Herein we discuss the clinical case of familial 
combined hyperlipidemia, a highly 
atherogenic disorder, that leads obviously to 
premature disability and to early mortality 
Patient B. 
43 years old 
Complaints 
• Retrosternal squeezing, burning pain, radiated 
to the left arm and left part of the neck, 
provoked by minimal physical activity (e.g. 
household chores), sometimes at rest, 
required nitroglycerin intake (up to 10 td), 
diminished effect of nitroglycerin  
• Palpitations 
• Irregular heart beats 
• Dyspnea, provoked by walking ground level up 
to 100 m 
• Lower extremities and face edema 
History of Presenting Complains 
• He feels sick since 2009, when at first episodic blood pressure 
elevations were occurred (max 180/120 mm Hg, usual 130/90 
mm Hg)  
• 2014 STEMI of LV inferior wall 
• 2015 recurrent STEMI  of LV anterior wall, septum, and apex  
• 2015 the patient was recommended an angiography, PCI with 
implantation of drug-eluting coronary stent; due to economic 
reasons, the patient had refused this procedure 
• 2017 hypertensive urgency, BP 180/120mm Hg 
• Regular (3-4 times per year) receive in-patient treatment with 
some positive dynamics; however, despite of regular out-
patient medication intake, the therapy effect is not lasting 
• Current deterioration occurred during last month: dyspnea 
was progressed, angina pain developed more often, physical 
tolerance decreased, effect of nitroglycerin diminished 
• The patient was hospitalized to the clinic 
 
Past Medical History 
• Since 2005 DM type 2, insulin dependent, 
severe course, decompensation 
FPG 13-17 mmol/L  
February 2018: diabetic foot, conservative 
treatment 
• February 2018: community acquired 
pneumonia in lower lobe of right lung, 
protracted course 
Drug History 
• Bisoprolol 5 mg od 
• Ramipril 5 mg od 
• Atorvastatin 80 mg od 
• Aspirin 75 mg od 
• Clopidogrel 75 mg od 
• Toracemide 5 mg od 
• Insulin glargine 20 IU 2 td 8-00, 20-00 
• Insulin regular human 10 IU 3 td before meal  
Alcohol and Smoking 
• The patient denies alcohol consumption  
 
• At present the patient does not smoke (since 
2015) 
• Before the patient smoked  
2 packs per day during 20 years = 40 pack-years 
Family History 
HTN T2DM, HTN, CHF 
Early death 
of relatives 
HTN MI at age 44, 
death at age 62 
T2DM, HTN 
HTN – essential hypertension, T2DM – type 2 diabetes mellitus, CHF – congestive heart 
failure  
Social History 
• Worked as a train driver assistant 
• Now he is working as a watchman 
• Lives in a flat, with his mother  
• Has no children 
 
Vital Signs 
• T           36, 4°C 
• PS         78 bpm 
• BP         130/80 mm Hg 
• RR         17 tpm 
• Height    183 cm 
• Weight    120 kg 
• BMI         35.8 kg/m² 
Middle aged male, looks older than the passport age, 
slightly depressive 
He is well oriented to space and time 
The posture is active 
Central type of obesity (waist circumference 146 cm, hips 
119 cm, waist/hip = 1.23) 
Skin is pink, on eyelids – xanthomas, trunk and 
extremities – multiple  eruptive xanthomas 
Visible changes of the neck  
shape are not detected  
Thyroid is palpable, in the left  
lobe a node ≈1 cmØ is  
detected  
Examination 
https://link.springer.com/referenceworkentry/10.1007%2F978-1-4471-4619-3_55 
 
Bronchial breathing in lungs to auscultation, 
diminished on basal parts of both lungs 
Peripheral pulses is weak, regular 
Apex beat is in 5th intercostal space 2 cm to the left of 
the left midclavicular line, 3 cm², weak 
 Soft S1 on apex and loud A2 heart sounds to 
auscultation, diffuse systolic murmur (grade II) at all 
points 
Abdomen is increased in size, participate in breathing 
actively; during palpation is soft and nontender 
Liver is enlarged (+3 cm), soft, nontender to palpation 
Spleen is not palpated 
Edema of the lower ½ of shins, foots 
Nocturia 1-2 per night 
Stool is regular, formed 
Examination 
Work up 
• Complete blood count 
• Urine analisis 
• Biochemical blood profile: Liver function tests,  
    Kidney function tests,  
    Cholesterol profile,  
    Thyroid function tests 
• B-NP, C-RP 
• ECG 
• Chest X-ray 
• Echocardiography, carotid US 
• Abdomen ultrasound 
• Thyroid ultrasound 
• Genetic counseling 
Complete Blood Count 
Results Reference range 
RBC  5.03 
 
1012/L 3.7-4.7
 
1012/L 
Hb 162 g/L 130-160 g/L 
WBC  6.0 
 
109/L 4.0-9.0
 
109/L 
Neutr Bands 2%  0.1
 
109/L 1-6% 0.0-0.2 
Neutr Segmented 54% 3.3
 
109/L 47,0-72%  1.7-7.7  
Eosinophils 3%  0.1
 
109/L 0,5-5,0%  0.0-0.6 
Basophils 1% 0.1
 
109/L 0,0-1,0%  0.0-0.2 
Lymphocytes 34% 2.1
 
109/L 19,0-37,0%  0.4-4.4 
Monocytes 6%  0.4
 
109/L 3,0-10,0%  0.0-0.8 
Thrombocytes  170 
 
109/L 180-320
 
109/L 
ESR 17 mm/h 1-10mm/h 
HCT 42.6% 40-48% 
Urine Analysis 
Results Reference range 
Colour  Yellow   
Specific gravity  1.016 1.001-1.040 
pH   6.0 5.0-7.0 
Protein  traces -- 
Glucose 170 mmol/L -- 
Ketone  bodies -- 
Leucocytes 1-2 /hpf 6-8/hpf 
Erithrocytes 0-1 /hpf single 
Transitional 
epithelium  
single single 
Casts  -- -- 
Crystals  -- -- 
Glucose  
Results  Reference range 
FPG (capillar) 16.6 mmol/L 3.3-5.5 mmol/L 
16.1 mmol/L 
16.2 mmol/L 
HB A1c, % 11.9 % <6,5 % 
9-00 13-00 17-00 21-00 6-00 
PG 16.1 
mmol/L 
16.73 
mmol/L 
16.14 
mmol/L 
16.46 
mmol/L 
15.9 
mmol/L 
Glycemic Profile 
Liver Function Tests 
Results  Reference range 
AlAT 16.3 U/L <33.0 
AsAT 3.0 U/L <32.0 U/L 
Bilirubin total 
              direct 
             indirect 
9.8 mkmol/L 
3.1 mkmol/L 
6.7 mkmol/L 
17-21 mkmol/L  
<5.0 mkmol/L  
AP  75  U/L 35-104 U/L 
LDH 156.53 U/L 135.0-214.0U/L 
Kidney Function Tests 
Results  Reference range 
Creatinine 87 µmol/L 62-106 µmol/L 
Urea  5.33 mmol/L 3.2-7.3 mmol/L 
Potassium 3.8 mmol/L 3.5-5.1mmol/L 
Sodium 141.3 mmol/L 136.0-145.0 mmol/L 
Chloride 102.4 mmol/L 98.0-107.0 mmol/L 
GFR  87.9 mL/min/1.73 m² 
by the MDRD Equation 
  
Cholesterol Profile 
Results  Reference range 
Total cholesterol 17.75 mmol/L* ≤ 5.2 mmol/L 
VLDL 3.41 mmol/L < 1 mmol/L 
LDL 13.64 mmol/L < 3.5 mmol/L 
HDL 0.7 mmol/L > 0.9 mmol/L 
Triglycerides  71.35 mmol/L* < 2.3 mmol/L 
Cholesterol/HDL ratio 17.57 mmol/L < 3.0 mmol/L 
*min TC, achieved by statin treatment 12.29 mmol/L 
**min TG, achieved by treatment 41.48 mmol/L 
Thyroid Function Tests 
Results  Reference range 
TTG 9.92 mg/dL 4.6-14.1 mg/dL 
T4 0.675  µIU/mL 0.270-4.20 µIU/mL 
ECG 
Sinus rhythm, regular, postinfarction cardiosclerosis (anterior, 
posterior wall, apex), violation of repolarisation  
Transthoracic Echocardiography 
• Sclerotic changes of aorta, aortic and mitral valves 
• Dilation of all heart chambers (LV EDD 66.8 mm, LV ESD 54.9 
mm, RVD 33.1 mm) 
• Hepertrophy of LV (LVPW 15.8 mm, VST 15.6 mm) and RV 
(6.8 mm) 
• Decreased contractility of LV, EF 36% 
• Hypokinesia of posterior wall, septa, apex, and anterio-
lateral well of the LV 
• Apical aneurism (28 mm length)  
• Diastolic dysfunction of LV 2 degree (pseudonormal) 
• Regurgitation:   mitral valve 2 degree  
    tricuspid valve 2 degree 
    pulmonary valve 1 degree  
• Pulmonary HTN 3 degree (41.3 mm Hg)  
Thyroid US 
Diffuse-nodular hyperplasia of the thyroid gland 
 
RL 60.1×20.5×23.5 mm 
LL 67.8×20.54×20.6 mm 
Ist 9.0 mm 
Left lobe node 8.3 mmØ 
Abdomen US 
• Liver is enlarged (craniocaudal dimension17.3 
cm, left lobe – 8.9 cm), echogenicity is 
increased, signs of steatosis 2 degree 
• Gall bladder content  is not homogeneous,  
stones are not evaluated 
•  Pancreas has increased echogenicity due to 
microfocal fibrous changes, caused by fatty 
infiltration 
• Spleen, Kidney Adrenal US are unremarkable  
Chest X-ray 
• Signs of venous congestion of the lungs 
• Initial signs of basal pneumofibrosis of both 
lungs 
• Lung roots are structured 
• Sinuses are free 
• Heart borders are displayed to the left 
• Aorta is enlarged 
Diagnosis 
Main: 
Familial combined hyperlipoproteinemia (Fredrickson 
type 2B).  
Acute coronary syndrome: Unstable angina IIB. 
Postinfarction (STEMI 2014, 2015) cardiosclerosis. 
Essential hypertension III degree III stage. Heart 
failure with left ventricular systolic and diastolic 
dysfunction, EF 36%. III functional class NYHA. Stage 
D AHA. Risk score 4 (very high). Type 2 diabetes 
mellitus, insulin dependent, severe course. 
Nonalcoholic fatty liver, 2 degree. 
 
Concomitant: Nodular goiter I degree, euthyroid state 
Management 
 Lifestyle Modification 
• Avoid smoking and alcohol intake 
• Lowering of body weight 
• Diet: restriction of saturated fats and simple 
sugars, low animal fat, low sodium (less 6 g)  
Treatment 
• Bisoprolol 5 mg od 
• Ramipril 5 mg od 
• Aspirin 75 mg od 
• Clopidogrel 75 mg od 
• Rosuvastatin  40 mg od 
• Choline Fenofibrate 135 mg 
• Insulin human NPH 20 IU 2 td 8-00, 20-00 
• Insulin human 10 IU 3 td before meal 
Prognosis 
• In this case prognosis is unfavorable 
• IHD and T2DM had developed in young age, 
the course of disease is progressive, 
symptoms are poorly controlled 
• Risk estimates based on risk charts and scores 
used in the general population, probably 
grossly underestimate the real risk of the FCH 
patient 
Conclusion 
For practitioners it is advised  
• monitoring the therapy not only by lab tests, but 
also by evaluating other instrumental and clinical 
markers of CHD 
• following the theory of “the lower, the better”, 
treating these patients in order to reduce their 
cholesterolemia and triglyceridemia to the best 
goals suggested by the international guidelines for 
cardiovascular diseases prevention, in association 
with a rigid control of all associated risk factors 
• screening family members of people with FCH is 
the most effective option for early detecting cases 
across the whole population and prevention of CVD 
and  CAD 
